Ascendis Pharma A (ASND) Depreciation & Amortization (CF) (2017 - 2025)

Ascendis Pharma A has disclosed Depreciation & Amortization (CF) across 9 years of filings, most recently posting $5.5 million for Q4 2025.

• Depreciation & Amortization (CF) for Q4 2025 came in at $5.5 million, up 17.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.8 million (down 20.59% YoY), and the FY2025 annual result was $20.0 million, up 8.67% from the prior year.
• Depreciation & Amortization (CF) came in at $5.5 million for Q4 2025 at Ascendis Pharma A, up from $4.6 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.5 million in Q4 2025 to a low of $4.2 million in Q2 2021.
• The 5-year median for Depreciation & Amortization (CF) is $4.7 million (2024), against an average of $4.7 million.
• Across the five-year window, Depreciation & Amortization (CF) surged 97.54% in 2021 and declined 10.37% in 2024, its largest moves.
• Ascendis Pharma A's Depreciation & Amortization (CF) stood at $4.8 million in 2021, then decreased by 3.02% to $4.6 million in 2022, then increased by 12.47% to $5.2 million in 2023, then decreased by 10.37% to $4.7 million in 2024, then advanced by 17.41% to $5.5 million in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $5.5 million (Q4 2025), $4.6 million (Q3 2025), and $4.7 million (Q2 2025), per Business Quant data.